Table 1.
Fixed effects, random effects, Bayesian random effects, and meta-regression estimates of the effectiveness of chlorhexidine bathing
| Summary estimate IRR (95% CI/CrI) | Meta-regression | |||
|---|---|---|---|---|
| Outcome | Fixed effects (I) | Random effects (DL) | Bayesian (RE) | Slope (95% CrI) |
| BSI | 0.79 (0.73, 0.86)a | 0.79 (0.60, 1.03) | 0.78 (0.45, 1.23) | –0.125 (–0.180, –0.071)a |
| CLABSI | 0.64 (0.56, 0.74)a | 0.49 (0.35, 0.68)a | 0.44 (0.26, 0.75)a | –0.050 (–0.123, 0.0231) |
| VAP | 0.83 (0.71, 0.98)a | 0.85 (0.67, 1.07) | 0.82 (0.57, 1.25) | –0.026 (–0.055, 0.002) |
| CAUTI | 1.04 (0.91, 1.18) | 0.98 (0.79, 1.21) | 0.93 (0.45, 1.66) | –0.008 (–0.048, 0.032) |
| MRSA-C | 0.59 (0.53, 0.65)a | 0.58 (0.47, 0.71)a | 0.59 (0.36, 0.94)a | –0.010 (–0.0154, 0.005) |
| MRSA-B | 0.66 (0.52, 0.84)a | 0.66 (0.52, 0.84)a | 0.64 (0.43, 0.91)a | –0.155 (–0.364, 0.054) |
| VRE-C | 0.58 (0.47, 0.73)a | 0.52 (0.33, 0.82)a | 0.53 (0.20, 1.55) | –0.027 (–0.065, 0.010) |
| VRE-B | 0.45 (0.25, 0.82)a | 0.63 (0.19, 2.08) | 0.53 (0.15, 2.26) | –1.006 (–1.830, –0.182)a |
| C-diff | 1.04 (0.91, 1.18) | 0.98 (0.48, 1.80) | 0.93 (0.48, 1.80) | 0.008 (–0.048, 0.032) |
aEstimates with 95% CrI excluding the null (0 for regression, and 1 for IRR)
IRR incidence rate ratio, I inverse variance, DL DerSimonian-Laird, RE random effects, CI confidence interval from Bayesian models, CrI credible interval from Bayesian models, BSI bloodstream infection, CAUTI catheter-associated urinary tract infections, C-diff Clostridium Difficile, CLABSI central line-associated bloodstream infection, MRSA methicillin-resistant Staphylococcus aureus, MRSA-C MRSA colonisation, MRSA-B MRSA-associated BSI, VAP ventilator-associated pneumonia, VRE vancomycin-resistant Enterococcus, VRE-C VRE colonisation, VRE-B VRE-associated BSI